Claus Zieler

Oncology

Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.

News

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.